GlassScriptPhysician profile
Kevin Thompson
NPI 1043772999
$5,075.50
in general payments reported to CMS, 2019-2025
27 companies · $2,891 in 2025
The $2,891 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $169 · 2023: $433 · 2024: $1,581 · 2025: $2,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,827 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,827.06 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $863.53 | 2022-2025 | Otezla, Tavneos, Enbrel |
| Abbvie INC. | $651.86 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $494.84 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $451.98 | 2024-2025 | Tremfya, Simponi Aria |
| Aurinia Pharma U.S., INC. | $388.22 | 2024-2025 | Lupkynis |
| Ucb, INC. | $359.79 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $231.32 | 2024-2025 | |
| Genzyme Corporation | $201.15 | 2023 | |
| Fresenius Kabi USA, LLC | $194.17 | 2023-2025 | Idacio, Tyenne |
| Ani Pharmaceuticals, INC. | $186.27 | 2024-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $172.01 | 2024-2025 | Tymlos |
| Organon LLC | $127.40 | 2025 | Hadlima |
| Mallinckrodt Hospital Products INC. | $125.45 | 2025 | Acthar |
| Pfizer INC. | $119.15 | 2024-2025 | |
| Genentech USA, INC. | $81.94 | 2024-2025 | Actemra, Gazyva |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73.71 | 2024-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.98 | 2023-2025 | Ofev |
| Glaxosmithkline, LLC. | $43.50 | 2022-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $40.82 | 2024-2025 | Orencia |
| Daiichi Sankyo INC. | $40.81 | 2025 | Injectafer |
| Sobi, INC | $40.36 | 2025 | |
| Alexion Pharmaceuticals, INC. | $35.28 | 2025 | Strensiq |
| Teleflex LLC | $29.33 | 2024-2025 | Trapliner |
| Kiniksa Pharmaceuticals International, Plc | $27.05 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $26.67 | 2024 | Lynparza, Keytruda |
| Octapharma USA, INC. | $20.00 | 2024 | Octagam Immune Globulin (Human) |
| Ambu INC. | $4.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.